Observational studyThe oncologist2026
Pulse wave analysis for quality-of-life associated early physiological changes during breast cancer chemotherapy: a proof-of-concept pilot study.
Observational study in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBreast cancer (BC) treatment, while essential, often impairs quality of life (QoL), typically assessed through -subjective reports. This single‑center, proof‑of‑concept observational study aimed to develop an objective and noninvasive monitoring method based on spectral analysis of the arterial blood pulse waveform (BPW). We investigated whether specific harmonic indices derived from the BPW could track physiological changes in BC patients following chemotherapy and correlate with patient-reported QoL improvements.
methodsRadial BPW signals were measured noninvasively in 41 BC patients before and after treatment, deriving harmonic indices including amplitude proportion and phase angle. QoL was assessed using the EORTC QLQ-C30 questionnaire. The pulse-distribution analysis (PDA) scoring model was used to classify patients based on their degree of improvement in Global-Health-Status scores.
resultsResults showed significant post-chemotherapy decreases in specific harmonic indices, suggesting normalized vascular dynamics. The PDA scoring model effectively classified patients by their Global-Health-Status improvement, achieving an AUC of 0.87 for extreme groups. PDA effect scores demonstrated a significant positive correlation with QoL changes (R = 0.332), outperforming heart rate and its variability. Notably, subgroup analysis revealed this correlation was substantially stronger in early-stage patients (Stage I: R = 0.787). Crucially, PDA scores were not confounded by age.
conclusionThis exploratory study suggests that the pulse‑wave‑based approach may serve as a low-cost, portable tool for monitoring early physiological changes in BC patients, potentially complementing traditional subjective QoL assessments in clinical practice. The enhanced sensitivity observed in early‑stage disease warrants further investigation. These proof‑of‑concept findings are hypothesis‑generating and require validation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.